Amdocs: Barclays Maintains Buy Rating with $111 Price Target

Barclays maintains a "Buy" rating on Amdocs (DOX) with a price target of $111.00. The company's shares closed at $88.87. TipRanks analyst Tavy Rosner has a 9.5% average return and 52.78% success rate. The Street has a "Strong Buy" consensus rating with a $103.00 average price target, implying a 15.90% upside from current levels.

Amdocs (DOX) reported strong third-quarter earnings, exceeding analyst expectations. The company's earnings per share (EPS) for the quarter ended June 2025 were $1.72, surpassing the Zacks Consensus Estimate of $1.71 per share [1]. This represents a year-over-year increase of $0.10 per share, or +6.2%, and an earnings surprise of +0.58%.

Revenues for the quarter were $1.14 billion, which exceeded the Zacks Consensus Estimate by 1.37% [1]. This is a decline of $0.11 billion, or -8.8%, compared to the same period last year. The company has now topped consensus revenue estimates two times over the last four quarters.

Amdocs has a mixed earnings outlook. The Zacks Rank, which considers earnings estimate revisions, currently ranks the stock as a "Hold" with a Zacks Rank #3 [1]. The current consensus EPS estimate for the coming quarter is $1.79, with revenues expected to be $1.14 billion.

Analysts have mixed ratings for Amdocs. Barclays maintains a "Buy" rating with a price target of $111.00, while TipRanks analyst Tavy Rosner has a 9.5% average return and 52.78% success rate [2]. The Street has a "Strong Buy" consensus rating with an average price target of $103.00, implying a 15.90% upside from current levels.

Amdocs' stock has underperformed the market so far this year, losing about 0.4% compared to the S&P 500's gain of 7.1% [1]. The company's shares closed at $88.87 on July 2, 2025.

References:
[1] https://www.nasdaq.com/articles/amdocs-dox-q3-earnings-and-revenues-beat-estimates
[2] https://www.nasdaq.com/articles/barclays-maintains-buy-rating-on-amdocs-dox-with-price-target-of-111-00